Official Title
Anosmia and / or Ageusia in COVID-19: Timeline, Treatment With Early Corticosteroid and Recovery
Brief Summary

Time to recover of Anosmia and / or ageusia and early corticosteroid use

Detailed Description

In a study of dexamethasone kinetics in two groups of 15 patients with community-acquired
pneumonia, one group was treated with dexamethasone 6 mg/day by mouth and the other with 4
mg/day intravenously. The apparent volume of distribution was 1 L/kg in both groups, but the
half-life after oral administration was approximately 7 hours, and after intravenous
administration 9 hours. The bioavailability of oral dexamethasone was 81% (95% CI = 54-121%).
However, the biological half-life of dexamethasone is much longer, of the order of 36-54 h
compared with 18-36 h for prednisolone.

Time to recover of Anosmia and / or ageusia and early corticosteroid use

Recruiting
COVID19
Anosmia

Drug: Early-Dexamethasone

early use of dexamethasone as early as laboratory evidence of high inflammatory markers
Other Name: Dexamethasone

Drug: Late dexamethazone

Use of dexamethasone on deterioration of the cases with increased severity
Other Name: Dexamethasone

Eligibility Criteria

Inclusion Criteria:

- Any case with COVID-19

- Age more than or equal to 18 years

- Mild to moderate severity

Exclusion Criteria:

- Diabetes

- Any contra-indication for the interventional drug

- Mentally disabled cases

Eligibility Gender
All
Eligibility Age
Minimum: 18 Years ~ Maximum: N/A
Countries
Egypt
Locations

Asalam
Maadi, Cairo, Egypt

Investigator: Emad R Issak, MD
Contact: 01272228989
dr.emad.r.h.issak@gmail.com

Contacts

Emad R Issak, MD
01272228989
dr.emad.r.h.issak@gmail.com

Emad R Issak, MD, Study Director
Assalam Clinics

NCT Number
MeSH Terms
COVID-19
Anosmia
Ageusia
Dexamethasone
Dexamethasone acetate
BB 1101